Roche to acquire gene therapy company Spark Therapeutics for $4.3bn
As per the terms of the merger agreement, Roche will buy each share of Spark Therapeutics at a price of $114.50. Founded in 2013, Spark Therapeutics is engaged
ENCell has entered into a strategic alliance and licencing agreement with Lucy Biotech for EN001, a next-generation mesenchymal stem cell therapy.
Johnson & Johnson Innovation facilitated the transaction. The collaboration focuses on several undisclosed integrin targets and will explore both inhibitors and activators of integrin function. To date, Morphic
Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF). METEORIC-HF is designed to evaluate the effect of treatment with omecamtiv